U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552987) titled 'A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome' on April 17.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%) compared with placebo in adult participants with stiff person syndrome (SPS).
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Stiff Person Syndrome
Intervention:
BIOLOGICAL: Kedrion IVIg 10%
Intravenous human normal immunoglobulin (IVIg) 10%
BIOLOGICAL: Human Albumin 5%
Human albumin solution 5%, diluted with saline 0.9% to a final concentration of 0.5%...